Oxford Biomedica plc (OTCMKTS:OXBDF – Free Report) – Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share estimates for Oxford Biomedica in a research note issued on Tuesday, April 30th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will post earnings of ($0.22) per share for the year, down from their prior estimate of ($0.19). The consensus estimate for Oxford Biomedica’s current full-year earnings is ($0.38) per share.
Oxford Biomedica Stock Up 30.2 %
Shares of OTCMKTS OXBDF opened at $3.79 on Friday. Oxford Biomedica has a 1 year low of $2.09 and a 1 year high of $6.02. The stock’s 50-day simple moving average is $2.54 and its 200-day simple moving average is $2.54.
Oxford Biomedica Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
Recommended Stories
- Five stocks we like better than Oxford Biomedica
- 3 Healthcare Dividend Stocks to Buy
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The How and Why of Investing in Biotech Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- 3 Ways To Invest In Coffee, Other Than Drinking It
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
